Recently, we have also found activated naïve B cells (CD21‐CXCR5‐) to be increased when comparing ACPA+ risk‐RA progressors to ACPA+ risk‐RA nonprogressors [43]. The gene discussed is CXCR5; the disease is rheumatoid arthritis.